B cell leukemia/lymphoma
Conditions
Interventions
Case series:therapy by CART
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
16 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. disease diagnosis: (1) Recurrent refractory B cell lymphoma (CD19 positive); (2) Recurrent refractory chronic lymphocytic leukemia (CD19 positive); (3) recurrent refractory acute B lymphocytic leukemia (CD19 positive). 2. Aged 16-80 years old; 3. Predict the survival period > 12 weeks; 4. Patients with unintentional liver and renal insufficiency; 5. Peripheral blood extraction can be performed and isolated peripheral blood cell (PBMCs) can be activated by CD3 /CD28 antibody and can be amplified in vitro; 6. Patients who have received allogeneic hematopoietic stem cell transplantation should be after the recovery period of 6 months. No obvious graft versus host disease, and dependence on immunosuppressive therapy; 7. Patients with no significant CD19 positive b-all caused central nervous system symptoms (such as meningeal leukemia); 8. No uncontrollable activity period infection, no active period HBV, HCV and HIV infection; 9. If a patient is a woman of reproductive period, she should be excluded from pregnancy and effective contraception during treatment; 10. Untreated steroids (such as hormone) were not used in three months; 11. No other gene therapy drugs or agents have been received.
Exclusion criteria
Exclusion criteria: 1. Prediction of survival <12 weeks; 2. Patients with cardiac renal insufficiency; 3. The symptoms of central nervous system (such as meningeal leukemia) caused by the obvious CD19 positive b-all. 4. Active stage infection, HBV, HCV and HIV infection; 5. Have received any other gene therapy drugs and preparations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate; | — |
Countries
China
Contacts
Public ContactTAN HUO
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed